HPV vaccination in France: Uptake, costs and issues for the National Health Insurance
- 27 April 2011
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 29 (19), 3610-3616
- https://doi.org/10.1016/j.vaccine.2011.02.064
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in DenmarkInternational Journal of Technology Assessment in Health Care, 2010
- Eligibility and willingness of first-year students entering university to participate in a HPV vaccination catch-up programEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2010
- Pharmacoepidemiological research using French reimbursement databases: yes we can!Pharmacoepidemiology and Drug Safety, 2010
- Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20–29 in the UKBritish Journal of Cancer, 2010
- Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic modelVaccine, 2008
- Modeling Cervical Cancer Prevention in Developed CountriesVaccine, 2008
- Economic evaluation of human papillomavirus vaccination in the United KingdomBMJ, 2008
- Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in SwitzerlandCurrent Medical Research and Opinion, 2008
- Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in FranceInternational Journal of Technology Assessment in Health Care, 2008
- Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccineVaccine, 2007